Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Benitec Biopharma Limited (BNTC : NSDQ)

• Company Description    Benitec Biopharma Limited is a biotechnology company which developed a patented gene silencing technology delivered by gene therapy called DNA directed RNA interference. The company is developing ddRNAi-based therapeutics for chronic and life-threatening human conditions including hepatitis C and B, drug resistant lung cancer and wet age-related macular degeneration. Benitec Biopharma Limited is based in Sydney, Australia. Number of Employees: 19

• Price / Volume Information    Yesterday's Closing Price: $15.65 Daily Weekly Monthly 20 Day Moving Average: 60,624 shares Shares Outstanding: 26.25 (millions) Market Capitalization: $410.82 (millions) Beta: 0.41 52 Week High: $17.15 52 Week Low: $9.10 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 16.36% 16.36% 12 Week 39.98% 34.20% Year To Date 23.91% 9.36%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 3940 Trust Way - Hayward,CA 94545 USA ph: 510-780-0819 fax: 61 (0)3 9966-9923 ikoffler@lifesciadvisors.com http://www.benitec.com

• General Corporate Information    Officers Jerel Banks - Chief Executive Officer; Chairman of the Board and Megan Boston - Chief Financial Officer; Director J. Kevin Buchi - Director Peter Francis - Director Edward Smith - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 08205P209 SIC: 2834 Fiscal Year Fiscal Year End: June Last Reported Quarter: 06/01/25 Next Expected EPS Date: 11/13/25 Share - Related Items Shares Outstanding: 26.25 Most Recent Split Date: 7.00 (0.06:1) Beta: 0.41 Market Capitalization: $410.82 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.35 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-2.64 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/13/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 4.22 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -% vs. Previous Quarter: -75.00% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 09/30/25 - - 06/30/25 - -46.19 03/31/25 - -38.26 ROA 09/30/25 - - 06/30/25 - -43.88 03/31/25 - -35.71 Current Ratio 09/30/25 - - 06/30/25 - 54.67 03/31/25 - 14.80 Quick Ratio 09/30/25 - - 06/30/25 - 54.67 03/31/25 - 14.80 Operating Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Net Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Pre-Tax Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Book Value 09/30/25 - - 06/30/25 - 3.71 03/31/25 - 4.16 Inventory Turnover 09/30/25 - - 06/30/25 - - 03/31/25 - - Debt-to-Equity 09/30/25 - - 06/30/25 - 0.01 03/31/25 - 0.01 Debt-to-Capital 09/30/25 - - 06/30/25 - 0.51 03/31/25 - 0.62

Powered by Zacks Investment Research ©